Linkedin
non-clinical-safety-solutions-logo

Regulatory Submission Authoring for IND, NDA, BLA & MAA

Overview

Regulatory expectations for nonclinical safety programs are complex, continually evolving, and often open to interpretation. Nonclinical Safety Solutions (NCSS) provides expert regulatory strategy and risk assessment services that ensure your development plans are scientifically justified, defensible, and aligned with global standards. With deep experience as both a senior industry toxicologist and a former FDA Pharmacology/Toxicology reviewer, Dr. Thomas D. Steele offers rare insight into what regulators expect—and how to position your data for successful interactions.

A strong regulatory strategy prevents delays, minimizes unexpected questions, and ensures your nonclinical package supports timely clinical progression. NCSS evaluates existing data, identifies risks or gaps, and develops a clear, cohesive plan that integrates toxicology, pharmacology, PK/ADME, and safety pharmacology into a unified safety narrative. Whether you’re preparing an IND, interpreting complex findings, or navigating new regulatory guidance, NCSS provides strategic clarity at every stage.

Effective risk assessment is equally essential. NCSS helps teams understand safety signals in the proper biological and regulatory context, determine human relevance, construct meaningful safety margins, and articulate scientifically sound rationales. This proactive approach not only strengthens your submissions but also empowers better internal decision-making throughout development.

Core Services Included in IND / NDA / MAA Submission Support

IND Nonclinical Section Preparation

  • Authoring and reviewing Module 2.4 (Nonclinical Overview) and Module 2.6 (Nonclinical Written & Tabulated Summaries)
  • Integration of pharmacology, PK/ADME, safety pharmacology, and toxicology data
  • Development of scientifically sound safety narratives
  • Clear justification of first-in-human dose and clinical dose selection strategy

NDA / MAA Nonclinical Section Support

  • Preparation of nonclinical summaries and overviews for advanced filings
  • Reconciliation of multi-study, multi-CRO datasets into a cohesive safety story
  • Identification of risks, gaps, and mitigation strategies before submission

Submission Strategy & Gap Identification

  • Evaluation of nonclinical package completeness and regulatory readiness
  • Identification of missing studies, insufficient endpoints, or unclear data integration
  • Recommendations for targeted follow-up studies or mechanistic investigations

Regulatory Interaction Support

  • Preparation of responses to FDA/EMA inquiries
  • Anticipation of regulatory concerns using direct reviewer insight
  • Drafting of briefing documents and slides for pre-IND, end-of-Phase 2, and Type B/C meetings

Scientific Storytelling & Data Integration

  • Creation of a clear, logical narrative that communicates risk relevance and human safety margins
  • Alignment of the safety rationale with clinical trial design, therapeutic context, and dose justification
  • Support for impurity Integration of cross-disciplinary datasets into a coherent justification for human exposure, off-target effects, and modality-specific challenges

Why This Service Matters

The nonclinical section is one of the most scrutinized parts of regulatory submissions. Poorly integrated datasets, unclear safety rationale, or insufficient justification can lead to clinical holds, FDA information requests, costly delays, or new study requirements. NCSS ensures your submission avoids these pitfalls by presenting your safety data with precision, clarity, and regulatory alignment.

Dr. Steele’s combined perspectives—from both the sponsor side and inside the FDA—enable NCSS to anticipate reviewer concerns before they emerge. This proactive, science-driven approach supports smoother review cycles, reduces regulatory friction, and strengthens the overall likelihood of approval.

If you need expert support preparing or reviewing the nonclinical sections of an upcoming submission, we invite you to request a consultation so NCSS can evaluate your needs and provide clear, regulator-informed guidance.

Frequently Asked Questions

1. What nonclinical information is required for an IND submission?

An IND requires integrated summaries of pharmacology, PK/ADME, safety pharmacology, genetic toxicology, and repeat-dose toxicology studies, along with scientific justification for starting dose and proposed clinical dosing.

2. Can a toxicology consultant help write the nonclinical sections of an IND/NDA?

Yes. Consultants like NCSS frequently write or review Modules 2.4 and 2.6 to ensure data are clearly communicated, scientifically justified, and aligned with FDA/EMA expectations.

3. What causes nonclinical-related IND delays or clinical holds?

Common issues include inadequate toxicology coverage, incomplete data, insufficient integration of PK/ADME with toxicology findings, or unclear justification for safety margins.

4. How early should companies begin planning for an IND submission?

Planning should begin months in advance to ensure data completeness, identify gaps, and build a well-structured safety narrative before regulatory deadlines.

5. Can NCSS help respond to FDA or EMA questions during review?

Absolutely. NCSS assists with crafting clear, defensible responses and preparing briefing materials to maintain momentum during regulatory evaluation.

6. Does NCSS support submissions outside the U.S., such as EMA MAA filings?

Yes. NCSS provides guidance aligned with ICH standards and supports U.S., EU, and global filings.

Expertise

Contact Us

To learn how NCSS can support your nonclinical and regulatory strategy, request a consultation